+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Cell Reprogramming (iPSC Generation) / Direct Reprogramming Services and Products Market, 2020-2030

  • ID: 5116508
  • Report
  • March 2020
  • Region: Global
  • 293 Pages
  • Roots Analysis

Enquire about COVID-19 updates for this product.

Enquire Now

FEATURED COMPANIES

  • 3P Biopharmaceuticals
  • Bioquark
  • DefiniGEN
  • K-Stem Cell
  • ONO Pharmaceutical
  • Seneca Biopharma
  • MORE

Overview

Over the years, advances in stem cell biology and regenerative medicine have enabled the discovery and development of a number of stem cell-based therapies. In fact, many believe that such interventions possess the potential to address several unmet needs related to the treatment of a wide range of diseases. Stem cell-based treatments are known for their ability to replace damaged cells and tissues, thereby, effectively reversing the adverse physiological effects they cause. However, challenges, such as scarcity of healthy stem cell donors, adverse immunological reactions upon treatment (owing to donor-recipient haplotype mismatches), and a number of ethical concerns related to the use of stem cells, are impeding progress in this field.

The discovery of induced pluripotent stem cells (iPSCs) by Shinya Yamanaka’s team in 2006 revolutionized stem cell research. Through his Nobel prize winning research, Yamanaka was able to reprogram mature somatic cells into a stem-like (pluripotent) state. This finding not only established the means to synthesize stem cells (thereby, offering a virtually endless supply of research material), but also provided the means to alleviate the social stigma surrounding stem cell research. Presently, cellular reprogramming is perceived as a powerful and versatile tool, with numerous applications in fundamental research and medicine.

It is worth mentioning that, today, many experts believe that stem cell therapies may be a possible solution to the COVID-19 pandemic. In fact, there are speculations, based on some evidence, that infected patients treated with stem cells may be more likely to successfully combat the symptoms of the disease. Research has also demonstrated that mesenchymal stem cells have the potential to be effectively used to treat SARS-CoV-2 induced pneumonia. Numerous partnerships have been inked amongst stakeholders in this domain, indicative to future growth of the market. Interestingly, start-ups/university spin-offs have been the flagbearers in this upcoming field of therapeutics and are also expected to sustain the research momentum, over the coming years.

Scope of the Report

The ‘Cell Reprogramming (iPSC Generation)/Direct Reprogramming Services and Products Market, 2020-2030’ report features an extensive study of the current market landscape and the future potential of cell reprogramming services and products in treating different chronic conditions. It features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain.

In addition to other elements, the study includes:

  • A review of the overall landscape of cell reprogramming market, featuring a list of over 30 cell reprogramming (iPSC Generation)/direct reprogramming service and product providers and a detailed analysis of these providers based on a number of parameters, such as year of establishment, company size, geographical location, location of manufacturing facilities, type of  service (iPSC generation and direct reprogramming), type of offering (in-house development, kit, service, technology (for licensing) and iPSC lines), type of technology (sendai virus-based reprogramming, mRNA reprogramming, episomal reprogramming and other technologies), type of vector used (viral vector, non-viral vector, mRNA and others), source cell for iPSC generation (fibroblasts, blood mononuclear cells, unspecified somatic cells and other cells), target indication(s), type of application (research and therapeutic) and additional service(s) offered (assay development, cell and tissue sourcing, cell banking, cell characterization, cell differentiation, cell sequencing, genome editing and other services).  
  • An insightful competitiveness analysis of iPSC generation and direct reprogramming service providers, based on supplier strength (based on a company’s employee count and years of experience) and service strength (which takes into account the number of reprogramming technologies offered, number of source cells used for iPSC generation used, number of target indications and number of manufacturing facilities).
  • Elaborate profiles of the industry players that offer cell reprogramming services and products. Each profiles features a brief overview of the company, its financial information (if available), details on cell reprogramming approaches, types of cell(s) utilized and differentiated, target indication(s), other drug discovery services offered, recent developments and an informed future outlook.
  • A detailed analysis of more than 540 completed, ongoing and planned clinical studies of various stem cell therapies, highlighting prevalent trends across various relevant parameters, such as trial registration year, phase of development, study design, current trial status, leading industry sponsors (in terms of number of trials conducted), study focus, type of stem cells, target indication(s), target therapeutic area(s), enrolled patient population and regional distribution of trials.
  • An analysis of the partnerships that have been established in this domain since 2016, covering R&D collaborations, licensing agreements, mergers and acquisitions, product development and/or commercialization agreements, clinical trial agreements, process development agreements, and other relevant deals.
  • A list of stem cell therapy developers/manufacturers, generated based on a detailed analysis of a set of relevant parameters (such as company size (employee count), type of cell (s), indication count and existing partnership(s)), which are anticipated to partner with cell reprogramming service and product providers in the foreseen future.  

One of the key objectives of the report was to understand the primary growth drivers and the future opportunity in cell reprogramming (iPSC generation)/ direct reprogramming services and products market. Based on multiple parameters, such as growth of the overall iPSC market, reprogramming cost and annual number of projects for stem cell therapies, we have provided an informed estimate of the likely evolution of the market in the short to mid-term and mid to long term, for the period, 2020-2030. The report also features the likely distribution of the current and forecasted opportunity within cell reprogramming services and products market across [A] type of technology offered (sendai virus-based reprogramming, mRNA reprogramming, episomal reprogramming and other technologies), [B] Source cells for iPSC generation  (fibroblasts, blood mononuclear cells, unspecified somatic cells and other cells), [C] type of application (research and therapeutic), and [D] key geographical regions (North America, Europe and Asia- Pacific and rest of the world). To account for the uncertainties associated with the development of reprogrammed cells and to add robustness to our model, we have provided three forecast scenarios, portraying the conservative, base and optimistic tracks of the market’s evolution.

The opinions and insights presented in the report were influenced by discussions held with senior stakeholders in the industry.

The report features detailed transcripts of interviews held with the following industry stakeholders:

  • Christiana Pires (Co-Founder and Chief Executive Officer, Asgard Therapeutics)
  • Julien Maruotti (Chief Scientific Officer, Phenocell)

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • 3P Biopharmaceuticals
  • Bioquark
  • DefiniGEN
  • K-Stem Cell
  • ONO Pharmaceutical
  • Seneca Biopharma
  • MORE

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Chapter Overview
3.2. Overview of Stem Cells
3.2.1. Classification of Stem Cells
3.2.1.1. Based on Source of Stem Cell
3.2.1.2. Based on Origin of Stem Cell
3.2.1.3. Based on Potency of Stem Cell
3.2.2. Routes of Administration of Stem Cell Therapies
3.2.3. Applications of Stem Cell Therapies
3.3. Introduction to Cell Reprogramming
3.3.1. Cell Reprogramming Approaches and Affiliated Technologies
3.4. Applications of Cell Reprogramming
3.5. Key Growth Drivers and Constraints

4. CURRENT MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Cell Reprogramming Service and Product Providers: List of Industry Players
4.2.1. Analysis by Year of Establishment
4.2.2. Analysis by Company Size
4.2.3. Analysis by Geographical Location
4.2.4. Analysis by Location of Manufacturing Facilities
4.2.5. Analysis by Type of Service
4.2.6. Analysis by Type of Offering
4.2.7. Analysis by Type of Technology
4.2.8. Analysis by Vector Used
4.2.9. Analysis by Source Cell for iPSC Generation
4.2.10. Analysis by Target Indication
4.2.11. Analysis by Application
4.2.12. Analysis by Additional Service(s) Offered
4.3. Cell Reprogramming Service and Product Providers: List of Non-Industry Players
4.3.1. Analysis by Geographical Location
4.3.2. Analysis by Type of Technology Used
4.3.3. Analysis by Type of Vector Used
4.3.4. Analysis by Source Cell for iPSC Generation
4.3. Cell Reprogramming: List of Affiliated Products Providers

5. COMPANY COMPETITIVENESS ANALYSIS
5.1. Chapter Overview
5.2. Assumptions and Key Parameters
5.3. Methodology
5.4. Competitiveness Analysis: iPSC Generation Service and Product Providers
5.5. Competitiveness Analysis: Direct Reprogramming Service and Product Providers

6. COMPANY PROFILES
6.1. Chapter Overview
6.2. Allele Biotechnology
6.2.1. Company Overview
6.2.2. Recent Developments and Future Outlook
6.3. ALSTEM
6.3.1. Company Overview
6.3.2. Recent Developments and Future Outlook
6.4. Applied Biological Materials
6.4.1. Company Overview
6.4.2. Recent Developments and Future Outlook
6.5. Axol Bioscience
6.5.1. Company Overview
6.5.2. Recent Developments and Future Outlook
6.6. Creative Bioarray
6.6.1. Company Overview
6.6.1.1. Recent Developments and Future Outlook
6.7. DefiniGEN
6.7.1. Company Overview
6.7.2. Recent Developments and Future Outlook
6.8. FUJIFILM Cellular Dynamics International
6.8.1. Company Overview
6.8.2. Recent Developments and Future Outlook
6.9. Lonza
6.9.1. Company Overview
6.9.2. Recent Developments and Future Outlook
6.10. Mogrify
6.10.1. Company Overview
6.10.2. Recent Developments and Future Outlook
6.11. REPROCELL
6.11.1. Company Overview
6.11.1.1. Recent Developments and Future Outlook
6.12. Stemnovate
6.12.1. Company Overview
6.12.2. Recent Developments and Future Outlook
6.14. Thermo fisher Scientific
6.14.1. Company Overview
6.14.1.1. Recent Developments and Future Outlook

7. CASE STUDY: CLINICAL TRIAL ACTIVITY IN STEM CELL THERAPY DEVELOPMENT
7.1. Chapter Overview
7.2. Scope and Methodology
7.3. Stem Cell Therapies: Clinical Trial Analysis
7.3.1. Analysis by Trial Registration Year
7.3.2. Analysis by Trial Phase
7.3.3. Analysis by Number of Patients Enrolled by Trial Registration Year
7.3.4. Analysis by Study Design
7.3.5. Analysis by Trial Recruitment Status
7.3.6. Analysis by Sponsor / Collaborator
7.3.7. Leading Industry Sponsors: Analysis by Number of Registered Trials
7.3.8. Analysis by Trial Focus
7.3.9. Analysis by Type of Stem Cell
7.3.10. Analysis by Therapeutic Area
7.3.11. Analysis by Type of Stem Cell and Therapeutic Area
7.3.12. Geographical Analysis by Number of Clinical Trials
7.3.13. Geographical Analysis by Trial Recruitment Status
7.3.14. Geographical Analysis by Enrolled Patient Population

8. PARTNERSHIPS AND COLLABORATIONS
8.1. Chapter Overview
8.2. Scope and Methodology
8.3. Cell Reprogramming Services and Products Market: List of Partnerships and Collaborations
8.3.1. Analysis by Year of Partnership
8.3.2. Analysis by Type of Partnership
8.3.3. Analysis by Year of Partnership and Type of Partner
8.3.4. Analysis by Type of Partnership and Type of Partner
8.3.5. Analysis by Type of Stem Cell
8.3.6. Analysis by Target Therapeutic Area
8.3.7. Analysis by Application
8.3.8. Most Active Players: Analysis by Number of Partnerships
8.3.9. Regional Analysis
8.3.10. Intercontinental and Intracontinental Agreements

9. LIKELY PARTNERSHIP OPPORTUNITIES
9.1. Chapter Overview
9.2. Scope and Methodology
9.3. Scoring Criteria and Key Assumptions
9.4. Stem Cell Therapy Developers: Likely Partners for Cell Reprogramming Service and Product Providers
9.4.1. Likely Partners for Cell Reprogramming Service and Product Providers in North America
9.4.2. Likely Partners for Cell Reprogramming Service and Product Providers in Europe
9.4.3. Likely Partners for Cell Reprogramming Service and Product Providers in Asia-Pacific and Rest of the World
9.5. Stem Cell Therapy Contract Manufacturers: Likely Partners for Cell Reprogramming Service and Product Providers
9.5.1. Likely Partners for Cell Reprogramming Service and Product Providers in North America
9.5.2. Likely Partners for Cell Reprogramming Service and Product Providers in Europe
9.5.3. Likely Partners for Cell Reprogramming Service and Product Providers in Asia-Pacific and Rest of the World

10. MARKET FORECAST
10.1. Chapter Overview
10.2. Scope and Methodology
10.3. Forecast Methodology and Key Assumptions
10.4. Global Cell Reprogramming Services and Products Market, 2020-2030
10.4.1. Global Cell Reprogramming Services and Products Market: Distribution by Type of Technology, 2020-2030
10.4.1.1. Cell Reprogramming Services and Products Market for Episomal Reprogramming, 2020-2030
10.4.1.2. Cell Reprogramming Services and Products Market for mRNA Reprogramming, 2020-2030
10.4.1.3. Cell Reprogramming Services and Products Market for Sendai Virus-based Reprogramming, 2020-2030
10.4.1.4. Cell Reprogramming Services and Products Market for Other Reprogramming Technologies, 2020-2030
10.4.2. Global Cell Reprogramming Services and Products Market: Distribution by Source Cell for iPSC Generation, 2020-2030
10.4.2.1. Cell Reprogramming Services and Products Market for Fibroblasts, 2020-2030
10.4.2.2. Cell Reprogramming Services and Products Market for Peripheral Blood Mononuclear Cells, 2020-2030
10.4.2.3. Cell Reprogramming Services and Products Market for Unspecified Somatic Cells, 2020-2030
10.4.2.4. Cell Reprogramming Services and Products Market for Other Cells, 2020-2030
10.4.3. Global Cell Reprogramming Services and Products Market: Distribution by Application, 2020-2030
10.4.3.1. Cell Reprogramming Services and Products Market for Research, 2020-2030
10.4.3.2. Cell Reprogramming Services and Products Market for Therapeutic Use, 2020-2030
10.4.4. Global Cell Reprogramming Services and Products Market: Distribution by Key Geographical Regions, 2020-2030
10.4.4.1. Cell Reprogramming Services and Products Market in North America, 2020-2030
10.4.4.2. Cell Reprogramming Services and Products Market in Europe, 2020-2030
10.4.4.3. Cell Reprogramming Services and Products Market in Asia-Pacific and Rest of the World, 2020-2030

11. EXECUTIVE INSIGHTS
11.1. Chapter Overview
11.2. Asgard Therapeutics
11.2.1. Company Snapshot
11.2.2. Christiana Pires, Co-Founder and Chief Executive Officer
11.3. Phenocell
11.3.1. Company Snapshot
11.3.2. Interview Transcript: Julien Maruotti, Chief Scientific Officer

12. CONCLUDING REMARKS

13. APPENDIX 1: TABULATED DATA

Note: Product cover images may vary from those shown
  • 3P Biopharmaceuticals
  • AA Partners (Ilaya)
  • Abcam
  • ACEA Biosciences
  • Addgene
  • Aegle Therapeutics
  • Allele Biotechnology
  • Alpine BioTherapeutics
  • ALSTEM
  • Altaco XXI
  • American CryoStem
  • Amgen
  • AMS Biotechnology
  • Angel Biotechnology
  • Angiocrine Bioscience
  • Anterogen
  • apceth Biopharma
  • Applied Biological Materials
  • Applied StemCell
  • Asahi Glass
  • Asgard Therapeutics
  • Aspire Health Science
  • Astellas Pharma
  • Athersys
  • Atlantic Bio GMP
  • Axcelead Drug Discovery Partners
  • Axiogenesis
  • Axis Biotec Brasil
  • Axol Bioscience
  • Azidus
  • Bayer
  • Baylx
  • BC Children’s Hospital Research Institute
  • Berlin Institute of Health
  • BHI Therapeutic Sciences
  • Bio Elpida
  • BioCardia
  • Biocenter Finland
  • BioGenCell
  • Bioinova sro
  • BioLamina
  • Biological Industries
  • Bioneer
  • BioNTech IMFS
  • Bioquark
  • BioreclamationIVT
  • BioRestorative Therapies
  • Bit Bio
  • Blood Reprogramming Technologies
  • BlueRock Therapeutics
  • Bone Therapeutics
  • BrainStorm Cell Therapeutics
  • Brigham and Women’s Hospital
  • Broad Institute
  • Bukwang Pharmaceutical
  • Caladrius Biosciences
  • Cancer Genetics
  • Capricor Therapeutics
  • CAR-T (Shanghai) Biotechnology
  • Cedars-Sinai
  • Celgene
  • Celixir
  • Cell and Gene Therapy Catapult
  • Cell Applications
  • Cell Reprogramming & Therapeutics
  • Cell Signaling Technology
  • Cell Tech Pharmed
  • Cell Therapies
  • Cellaria Biosciences
  • Cellerant Therapeutics
  • CELLforCURE
  • CellProthera
  • Cellular Biomedicine Group
  • Cellular Engineering Technologies
  • Cellular Reprogramming
  • Censo Biotechnologies
  • Center for iPS Cell Research and Application, Kyoto University
  • Center for Molecular Medicine, Karolinska University Hospital
  • Center for Regenerative Therapies, German Research Foundation
  • CENTOGENE
  • Cesca Therapeutics
  • CHA Biolab
  • Chabiotech
  • Charles River
  • Chiesi Farmaceutici
  • China Regenerative Medicine International
  • Cincinnati Children’s Hospital Medical Center
  • Cleans Cells
  • Cognate BioServices
  • Columbia Stem Cell Initiative
  • Cook MyoSite
  • Corestem
  • Creative Bioarray
  • Creative Biolabs
  • Cryosite
  • CureCell
  • Cynata Therapeutics
  • Cytopeutics
  • DefiniGEN
  • DiscGenics
  • Editas Medicine
  • EHL Bio
  • EpiBone
  • Escape Therapeutics
  • ESI BIO
  • European Bank for induced pluripotent Stem Cells
  • European Institute for the Biology of Ageing
  • Ever Supreme Bio technology
  • Evercyte
  • Evotec
  • Evotec
  • Fate Therapeutics
  • Feinberg School of Medicine
  • Ferrer Internacional
  • Fibrocell Science
  • Fortuna Fix
  • FUJIFILM Cellular Dynamics
  • Gamida Cell
  • GE Healthcare
  • GenCure
  • GeneCopoeia
  • Genenta Science
  • Genome Engineering and iPSC Center
  • German Stem Cell Research Network
  • GlaxoSmithKline
  • Global Cell Med
  • Gwo xi Stem Cell
  • Harvard Stem Cell Institute
  • Harvard University Stem Cell Institute
  • Hemogenyx
  • Hemostemix
  • Histocell
  • Hitachi Chemical
  • Hope Biosciences
  • Hubei Hongyuan Pharmaceutical technology
  • Human Pluripotent Stem Cell Core Facility
  • Icahn School of Medicine
  • ID Pharma
  • Indiana University
  • Indiana University Research and Technology
  • InSphero
  • Institute of Molecular Biotechnology (IMBA)
  • Institute of Molecular Biotechnology, Austrian Academy of Sceinces
  • International Stem Cell Corporation
  • iPS Academia Japan
  • iXCells Biotechnologies
  • Japan Regenerative Medicine
  • Japan Tissue Engineering
  • Japan Tissue Engineering (J-TEC)
  • jCyte
  • Kadimastem
  • Kangstem Biotech
  • KBI Biopharma
  • Kemwell Biopharma
  • KLSMC Stem Cells
  • K-Stem Cell
  • LAI International
  • Leiden University Medical Center
  • Life & Brain
  • LifeCell
  • Lineage Cell Therapeutics
  • Longeveron
  • Lonza
  • Magellan Stem Cells
  • Magenta Therapeutics
  • MangoGen Pharma
  • MaSTherCell
  • McEwen Stem Cell Institute
  • Med Cell Bahamas
  • Medeor Therapeutics
  • Medicines Discovery Catapult
  • MEDINET
  • Medipost
  • Melbourne Stem Cell Centre
  • Memorial Sloan Kettering Cancer Center
  • Merck
  • Meridigen Biotech
  • Mesoblast
  • Metrion Biosciences
  • MilliporeSigma
  • Miltenyi Biotec
  • Minovia Therapeutics
  • Mogrify
  • National Eye Institute
  • Nature Cell
  • Ncardia
  • Ncardia
  • NeuCyte
  • NeuroGeneration
  • New York Blood Center
  • Newcastle University
  • Newcells Biotech
  • NextCell Pharma
  • Nikon CeLL innovation
  • Nipro
  • Nohla Therapeutics
  • Noray Biosciences Group
  • Novadip Biosciences
  • Novartis Pharmaceuticals
  • NuVasive
  • ONO Pharmaceutical
  • Orchard Therapeutics
  • Orgenesis
  • Orthofix
  • Osiris Therapeutics
  • Oslo University Hospital
  • Ottawa Hospital Research Institute
  • Penn's Institute for Regenerative Medicine
  • Personalized Stem Cells
  • Pharmicell
  • Phenocell
  • Pluriomics
  • Pluristem Therapeutics
  • Plus Therapeutics
  • Promethera Biosciences
  • Propagenix
  • Protide Pharmaceuticals
  • Provia Labs
  • Q Therapeutics
  • R3 Stem Cell
  • Radboudumc Stem Cell Technology Center
  • R-Bio
  • Regeneus
  • Regenexx
  • Reliance Life Sciences
  • ReNeuron
  • ReproCell
  • RheinCell Therapeutics
  • Riordan Technologies
  • Rockland Immunochemicals
  • ROHTO Pharmaceutical
  • Roslin Cells
  • RTI Surgical
  • S.Biomedics
  • Salvat
  • Samsung BioLogics
  • SanBio
  • Sanofi
  • Sanquin
  • SBH Sciences
  • Sclnow Biotechnology
  • SCM Lifescience
  • SCM Lifescience
  • Seneca Biopharma
  • Sentien Biotechnologies
  • Shandong Qilu Stem Cells Engineering
  • Shenzhen Hornetcorn Biotechnology
  • Stem Cell Medicine
  • Stem Med
  • STEMCELL Technologies
  • StemCore
  • Stemedica Cell Technologies
  • Stemgenics
  • Steminent Biotherapeutics
  • Stemmatters
  • Stemnovate
  • Stempeutics Research
  • Stryker
  • Swiss Medica XXI Century
  • System Bioscience
  • Taiwan Bio Therapeutics
  • Taiwan Human Disease iPSC Consortium
  • Takara Bio
  • Takara Bio
  • Takeda
  • Talaris Therapeutics
  • Terumo
  • The Emmes Company
  • The University of California, Irvine
  • The University California, San Diego
  • The University Hospital of Dusseldorf
  • The University of Wisconsin
  • Thermo Fisher Scientific
  • Tianhe Stem Cell Biotechnologies
  • Tianjin Ever Union Biotechnology
  • Tianjin Weikai Biological Engineering
  • TICEBA
  • Tocris Bioscience
  • TreeFrog Therapeutics
  • Turn Biotechnologies
  • U.S. Stem Cell
  • United Therapeutics
  • Universal Cells
  • University Medical Center Göttingen
  • University of Bonn
  • University of Cambridge
  • University of Colorado
  • University of Florida College of Medicine
  • University of Helsinki
  • University of Texas
  • University of Utah
  • University of Washington’s Institute for Stem Cell and Regenerative Medicine
  • University at Buffalo
  • VcanBio Center for Translational Biotechnology
  • Vericel
  • VetStem
  • ViaCyte
  • Viscofan BioEngineering
  • Waisman Biomanufacturing
  • WuXi Advanced Therapies
  • Yale Stem Cell Center
  • YposKesi
Note: Product cover images may vary from those shown

 

 

Loading
LOADING...

Adroll
adroll